• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Ardelyx Inc.

    6/25/25 4:01:19 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARDX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Ardelyx, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    039697107

    (CUSIP Number)


    06/17/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    039697107


    1Names of Reporting Persons

    Millennium Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    12,099,947.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    12,099,947.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    12,099,947.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    039697107


    1Names of Reporting Persons

    Millennium Group Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    12,099,947.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    12,099,947.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    12,099,947.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    039697107


    1Names of Reporting Persons

    Israel A. Englander
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    12,099,947.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    12,099,947.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    12,099,947.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Ardelyx, Inc.
    (b)Address of issuer's principal executive offices:

    400 Fifth Avenue, Suite 210, Waltham, Massachusetts 02451
    Item 2. 
    (a)Name of person filing:

    Millennium Management LLC Millennium Group Management LLC Israel A. Englander
    (b)Address or principal business office or, if none, residence:

    Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
    (c)Citizenship:

    Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    039697107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See response to Item 9 on each cover page.
    (b)Percent of class:

    See response to Item 11 on each cover page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See response to Item 5 on each cover page.

     (ii) Shared power to vote or to direct the vote:

    See response to Item 6 on each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See response to Item 7 on each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit I
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Millennium Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:06/24/2025
     
    Millennium Group Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:06/24/2025
     
    Israel A. Englander
     
    Signature:/s/ Israel A. Englander
    Name/Title:Israel A. Englander
    Date:06/24/2025
    Exhibit Information

    Exhibit I: Joint Filing Agreement, dated as of June 24, 2025, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

    Get the next $ARDX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ARDX

    DatePrice TargetRatingAnalyst
    6/18/2025$10.00Buy
    H.C. Wainwright
    5/2/2025$11.00Strong Buy → Outperform
    Raymond James
    3/7/2025Buy
    Ladenburg Thalmann
    3/4/2025$14.00Buy
    BTIG Research
    11/11/2024$11.00 → $5.50Buy → Neutral
    H.C. Wainwright
    7/2/2024$15.00 → $7.00Overweight → Neutral
    Piper Sandler
    4/5/2024$14.00Outperform
    Leerink Partners
    12/18/2023$12.00Strong Buy
    Raymond James
    More analyst ratings

    $ARDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bazemore Robert B was granted 41,551 shares (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      6/23/25 8:44:06 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Rodgers Richard J was granted 63,019 shares, increasing direct ownership by 18% to 413,543 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      6/23/25 8:42:03 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Parsey Merdad was granted 15,235 shares, increasing direct ownership by 36% to 57,291 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      6/23/25 8:41:17 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mott David M bought $725,880 worth of shares (200,000 units at $3.63), increasing direct ownership by 7% to 2,896,871 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      6/18/25 9:28:07 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mott David M bought $737,260 worth of shares (200,000 units at $3.69), increasing direct ownership by 8% to 2,696,871 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      6/11/25 9:40:28 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mott David M bought $329,120 worth of shares (100,000 units at $3.29), increasing direct ownership by 4% to 2,496,871 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      5/19/25 5:02:11 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Ardelyx with a new price target

      H.C. Wainwright resumed coverage of Ardelyx with a rating of Buy and set a new price target of $10.00

      6/18/25 7:56:36 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx downgraded by Raymond James with a new price target

      Raymond James downgraded Ardelyx from Strong Buy to Outperform and set a new price target of $11.00

      5/2/25 8:06:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann resumed coverage on Ardelyx

      Ladenburg Thalmann resumed coverage of Ardelyx with a rating of Buy

      3/7/25 8:02:22 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

      WALTHAM, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Monday, August 4, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the second quarter of 2025. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under th

      7/21/25 8:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer

      WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Kelliher, formerly Executive Vice President, Corporate Development and Strategy, has been promoted to Chief Business Officer, and James P. Brady has joined the company as Chief Human Resources Officer. Since joining Ardelyx in March 2024, Mr. Kelliher has established himself as important leader driving Ardelyx's long-term growth and value creation strategies. In his newly expanded role as Chief Business Officer, Mr.

      6/2/25 4:05:01 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025

      WALTHAM, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, President and CEO, will participate in a fireside chat at the Jefferies Global Healthcare Conference 2025 on Wednesday, June 4, 2025 at 8:10 am ET in New York. To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ardelyx.com/. A replay of the fireside chat will be available on the Ardelyx website for 30 days following the event.

      5/21/25 8:00:03 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for XPHOZAH issued to ARDELYX INC

      Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

      10/20/23 4:37:52 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for XPHOZAH issued to ARDELYX INC

      Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

      10/18/23 4:43:04 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for XPHOZA™ issued to ARDELYX INC

      Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

      10/18/23 4:37:08 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    SEC Filings

    See more
    • Ardelyx Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - ARDELYX, INC. (0001437402) (Filer)

      7/3/25 8:49:21 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Ardelyx Inc.

      SCHEDULE 13G - ARDELYX, INC. (0001437402) (Subject)

      6/25/25 4:01:19 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - ARDELYX, INC. (0001437402) (Filer)

      6/18/25 5:23:41 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Leadership Updates

    Live Leadership Updates

    See more
    • Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer

      WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Kelliher, formerly Executive Vice President, Corporate Development and Strategy, has been promoted to Chief Business Officer, and James P. Brady has joined the company as Chief Human Resources Officer. Since joining Ardelyx in March 2024, Mr. Kelliher has established himself as important leader driving Ardelyx's long-term growth and value creation strategies. In his newly expanded role as Chief Business Officer, Mr.

      6/2/25 4:05:01 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

      WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Merdad Parsey, M.D., Ph.D. to the company's board of directors. "We are thrilled to welcome Merdad to our board of directors," said Mike Raab, president and chief executive officer of Ardelyx. "Merdad is a veteran biotech leader and clinician with a commitment to patients that aligns with the Ardelyx vision of a healthier tomorrow for patients. His broad leadership experience spans the entire pharmaceutical d

      4/29/25 8:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer

      WALTHAM, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Eric Foster as the company's Chief Commercial Officer. Mr. Foster is an experienced leader with more than 23 years of commercial experience for significant global biotech and pharmaceutical companies across numerous complex rare disease and specialty markets. Mr. Foster will be responsible for leading all commercial strategies for the company's two first-in-class medicines, IBSRELA® (tenapanor) and XPHOZAH® (te

      8/8/24 8:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.

      SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

      11/14/24 4:08:33 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.

      SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

      7/10/24 6:32:11 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ardelyx Inc. (Amendment)

      SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

      2/13/24 5:26:59 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Financials

    Live finance-specific insights

    See more
    • Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

      WALTHAM, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Monday, August 4, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the second quarter of 2025. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under th

      7/21/25 8:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

      Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales revenue of $23.4 million  Company ends Q1 with $214.0 million in cash, cash equivalents and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2025 and provided a business update. "Ardelyx deliver

      5/1/25 4:01:51 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

      WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, May 1, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the first quarter of 2025. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Inves

      4/17/25 8:00:56 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care